Provided by Tiger Trade Technology Pte. Ltd.

Anaptysbio Inc

63.02
+0.30000.48%
Post-market: 63.020.00000.00%17:38 EDT
Volume:224.18K
Turnover:14.07M
Market Cap:1.81B
PE:-136.97
High:64.00
Open:62.38
Low:60.92
Close:62.72
52wk High:68.39
52wk Low:15.40
Shares:28.75M
Float Shares:17.26M
Volume Ratio:0.27
T/O Rate:1.30%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4601
EPS(LYR):-0.4601
ROE:-24.49%
ROA:7.06%
PB:48.69
PE(LYR):-136.97

Loading ...

UK Stocks-Factors to watch on January 9

Reuters
·
Jan 09

BRIEF-Anaptys Files Motion To Dismiss Tesaro'S Claim Of Anticipatory Breach Of Contract In Ongoing Litigation

Reuters
·
Jan 09

AnaptysBio Seeks Dismissal of Tesaro’s Breach Claim in Delaware Court

Reuters
·
Jan 09

Anaptys Files Motion to Dismiss Tesaro’s Claim of Anticipatory Breach of Contract in Ongoing Litigation Against Tesaro, a GSK Subsidiary

THOMSON REUTERS
·
Jan 09

AnaptysBio Inc - Trial in Anaptys and Tesaro/GSK Dispute Set for July 14-17, 2026

THOMSON REUTERS
·
Jan 09

AnaptysBio CFO Dennis Mulroy Reports Disposal of Common Shares

Reuters
·
Jan 09

UBS Upgrades AnaptysBio to Buy From Neutral, Adjusts Price Target to $70 From $20

MT Newswires Live
·
Jan 07

AnaptysBio to Split Biopharma Operations and Royalty Assets by 2026

Reuters
·
Jan 07

AnaptysBio CFO Dennis Mulroy Reports Sale of Common Shares

Reuters
·
Dec 24, 2025

AnaptysBio CFO Dennis Mulroy Reports Disposal of Common Shares

Reuters
·
Dec 19, 2025

AnaptysBio Is Maintained at Overweight by Barclays

Dow Jones
·
Dec 18, 2025

U.S. RESEARCH ROUNDUP-Airbnb, Garrett Motion, Range Resources

Reuters
·
Dec 17, 2025

BRIEF-Vanda Announces Submission Of Biologics License Application To The FDA For Imsidolimab For The Treatment Of Generalized Pustular Psoriasis

Reuters
·
Dec 15, 2025

Vanda Announces Submission of Biologics License Application to the FDA for Imsidolimab for the Treatment of Generalized Pustular Psoriasis

THOMSON REUTERS
·
Dec 15, 2025

Vanda Pharmaceuticals: Priority Review Would Establish 6-Month Review Cycle, Potential Imsidolimab FDA Approval for Gpp Treatment as Early as Mid-2026

THOMSON REUTERS
·
Dec 15, 2025

U.S. RESEARCH ROUNDUP-BioNTtech, GE Vernova, Synopsys

Reuters
·
Dec 11, 2025

A Look at AnaptysBio's Valuation as Litigation With GSK Over Jemperli Royalties Draws Investor Focus

Simply Wall St.
·
Nov 28, 2025

BRIEF-AnaptysBio's Complaint Against Tesaro For Breaching Agreement Was Publicly Filed On Nov 26 - SEC Filing

Reuters
·
Nov 27, 2025

AnaptysBio Inc - on Nov 26, Co's Complaint Against Tesaro for Breaching Agreement Was Publicly Filed - SEC Filing

THOMSON REUTERS
·
Nov 27, 2025

Wedbush Sticks to Its Buy Rating for AnaptysBio (ANAB)

TIPRANKS
·
Nov 26, 2025